David

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

301 0 Myeloproliferative Disease

Dr. J.J. Kiladjian ASH 2018 Headline Research Studies

Přehrát Přidat do

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter

144 0 Myeloproliferative Disease

Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys in Patients with Myelofibrosis

Přehrát Přidat do

Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter

183 0 Myeloproliferative Disease

Real World Risk Assessment and Treatment of patients with Myelofibrosis at Community Oncology Practices in the U.S.

Přehrát Přidat do

PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017

473 0 Acute Lymphoblastic Leukemia

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two - year results from the First Prospective Randomized Controlled Trial

Přehrát Přidat do

PV Reporter interviews Dr. Raajit Rampal at ASH 2017

279 0 Acute Lymphoblastic Leukemia

Advanced Forms of MPNs are Associated with Chromosomal Abnormalities Involved in Disease Progression

Přehrát Přidat do

PV Reporter interviews Dr. Michael Grunwald at ASH 2017

387 0 Acute Lymphoblastic Leukemia

Patient reported symptom burden and peripheral blood counts among PV patients.

Přehrát Přidat do

Dr Rampal at ASH 2016 with PV Reporter

944 0 Acute Lymphoblastic Leukemia

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center in New York City, interviews with David Wallace, PV Reporter. Discussing clinical research in MPNs at ASH 2016. Dr. Rampal presented pre-clinical data from a three drug combo in animal models.

Přehrát Přidat do

Dr Kiladjian at ASH 2016 with PV Reporter

847 0 Acute Lymphoblastic Leukemia

Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2016. Discussing Outcomes of Patients with MPNs after Interferon-Alpha (IFN) Therapy Discontinuation.

Přehrát Přidat do

David

PV Reporter interviews Dr. Michael Grunwald at ASH 2017

Datum přidání (nejnovější)

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter

Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter

PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017

PV Reporter interviews Dr. Raajit Rampal at ASH 2017

PV Reporter interviews Dr. Michael Grunwald at ASH 2017

Dr Rampal at ASH 2016 with PV Reporter

Dr Kiladjian at ASH 2016 with PV Reporter

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2

Dr. J.J. Kiladjian ASH 2018 Headline Research Studies

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter

Ruxopeg Phase 1-2 Trial of Ruxolitinib and Pegasys in Patients with Myelofibrosis

Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter

Real World Risk Assessment and Treatment of patients with Myelofibrosis at Community Oncology Practices in the U.S.

PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two - year results from the First Prospective Randomized Controlled Trial

PV Reporter interviews Dr. Raajit Rampal at ASH 2017

Advanced Forms of MPNs are Associated with Chromosomal Abnormalities Involved in Disease Progression

PV Reporter interviews Dr. Michael Grunwald at ASH 2017

Patient reported symptom burden and peripheral blood counts among PV patients.

Dr Rampal at ASH 2016 with PV Reporter

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center in New York City, interviews with David Wallace, PV Reporter. Discussing clinical research in MPNs at ASH 2016. Dr. Rampal presented pre-clinical data from a three drug combo in animal models.

Dr Kiladjian at ASH 2016 with PV Reporter

Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2016. Discussing Outcomes of Patients with MPNs after Interferon-Alpha (IFN) Therapy Discontinuation.

Dr. Jean Jacques Kiladjian ASH 2018 interview with David ...